Open AccessThe relationship between depression and metabolic control parameters in type 2 diabetic patients: A cross‐sectional and feasibility interventional study
Author(s) -
Khassawneh Adi H.,
Alzoubi Abdallah,
Khasawneh Aws G.,
Abdo Nour,
AbuNaser Dania,
AlMistarehi AbdelHameed,
Albattah Malak F.,
Kheirallah Khalid A.
Publication year - 2021
Publication title -
international journal of clinical practice
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.756
H-Index - 98
eISSN - 1742-1241
pISSN - 1368-5031
DOI - 10.1111/ijcp.13777
Subject(s) - medicine , escitalopram , depression (economics) , diabetes mellitus , patient health questionnaire , type 2 diabetes mellitus , cross sectional study , context (archaeology) , type 2 diabetes , metabolic control analysis , physical therapy , depressive symptoms , endocrinology , antidepressant , pathology , economics , macroeconomics , paleontology , biology , hippocampus
Abstract Background Substantial evidence supports a bidirectional relationship between diabetes and clinical depression. However, little is known about the effect of treating one condition on the control of the other. Thus, this study aimed to determine the prevalence of depression among Type II diabetes mellitus (T2DM) patients and to assess the efficacy and feasibility of escitalopram treatment of depression on their metabolic control parameters. Methods T2DM patients attending primary care clinics in the North of Jordan were enrolled in a cross‐sectional study during the period from February to December 2019 (n = 157). Depressive symptoms were screened utilising the patient health questionnaire‐9 (PHQ‐9) tool. Metabolic control was assessed by measurement of glycated haemoglobin (HbA1c), triglycerides, cholesterol, low‐density lipoprotein (LDL) and high‐density lipoprotein (HDL). Patients with moderate to severe depressive symptoms by PHQ‐9 (n = 58) were interviewed by a psychiatrist to confirm a clinical diagnosis of depression. Eligible depressed patients were administered escitalopram 10 mg orally once daily for 3 months (n = 12). Thereafter, depressive symptoms and metabolic control measures were reassessed. Results The prevalence of moderate to severe depressive symptoms among T2DM patients, according to PHQ‐9, was 36.94%, while the prevalence of clinical depression based on interview was 7.64%. Baseline PHQ‐9 scores correlated significantly with baseline levels of HbA1c, HDL, cholesterol and triglycerides. Escitalopram treatment intervention resulted in significant improvement of PHQ‐9 scores without significantly improving any of the metabolic control measures. Conclusion The relationship between depression and T2DM in the context of metabolic syndrome is plausible. However, our results show that escitalopram treatment may not be associated with significant improvement in metabolic control parameters among these patients. Our study has laid the groundwork for future randomised clinical trials with larger sample size and longer follow‐up.